Reduced expression of p27(Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma

Cancer Letters

Volumn 151, Issue 2, 2000, Pages 217-222

  Kudo, Yasusei ^a   Takata, Takashi ^a   Ogawa, Ikuko ^b   Zhao, Ming ^a   Sato, Sunao ^a   Takekoshi, Toshitsugu ^a   Miyauchi, Mutsumi ^a   Nikai, Hiromasa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Early invasive; Ki 67; Oral squamous cell carcinoma; p27(Kip1); p53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P27; PROTEIN P53;

ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LONGITUDINAL STUDIES; MICROTUBULE-ASSOCIATED PROTEINS; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0034647022     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00419-X     Document Type: Article

References (21)

1. Sherr C.J. phase progression: cycling on cue. Cell. 79:1994;551-555.
2. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
3. Sheer C.J., ancer C. cell cycles. Science. 274:1996;1672-1677.
4. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
5. Polyak K., Lee M.H., Erdjument-Bromage H., Tempst P., Massague J. Cloning of p27Kip1, a cyclin-Cdk inhibitor and potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
6. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
7. Porter P.J., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat. Med. 2:1997;222-225.
8. Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari,C L., andhu S., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K.I., Slingerland J.M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 2:1997;227-230.
9. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., Jessup J.M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 2:1997;231-234.
10. Fredersdorf S., Burns J., Milne A.M., Packham G., Fallis L., Gillett C.E., Royds J.A., Peston D., Hall P.A., Hanby A.M., Barnes D.M., Shousha S., O'Hare M.J., Lu X. High level expression of p27Kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci. USA. 94:1997;6380-6385.
11. Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res. 88:1997;625-629.
12. Kudo Y., Takata T., Yasui W., Ogawa I., Miyauchi M., Takekoshi T., Tahara E., Nikai H. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior of oral squamous cell carcinomas. Cancer. 83:1998;2447-2455.
13. Japan Society for Head and Neck Cancer. General Rules for Clinical and Pathological Studies on Head and Neck Cancer, 2nd Edition, Kanehara, Tokyo, 1991.
14. Baas I.O., Mulder J.W.R., Offerhaus G.J.A., Vogelstein B., Hamilton S.R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 172:1994;5-12.
15. Marx J., any M. gene changes found in cancer. Science. 246:1989;1386-1388.
16. Fearon E.R., Vogelstein B. genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
17. Girod S.C., Krueger G., Pape H.D. p53 and Ki-67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int. J. Oral. Maxillofac. Surg. 22:1993;285-288.
18. Thomas G.V., Szigeti K., Murphy M., Draetta G., Pagano M., Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastasis. Am. J. Pathol. 153:1998;681-687.
19. St. Croix B., Sheehan C., Rak J.W., Florenes V.A., Slingerland J.M., Kerbel R.S. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27Kip1. J. Cell Biol. 142:1998;557-571.
20. Cruz I.B., Snijders P.J., Meijer C.J., Braakhuis B.J., Snow G.B., Walboomers J.M., van der Waal I. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J. Pathol. 184:1998;360-368.
21. Bertorelle R., Esposito G., Del Mistro A., Belluco C., Nitti D., Lise M., Chieco-Bianchi L. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am. J. Surg. Pathol. 19:1995;463-471.